Персонализированный подход к назначению прямых оральных антикоагулянтов: от теории к практике
Персонализированный подход к назначению прямых оральных антикоагулянтов: от теории к практике
Скрипка А.И., Когай В.В., Листратов А.И. и др. Персонализированный подход к назначению прямых оральных антикоагулянтов: от теории к практике. Терапевтический архив. 2019; 91 (7): 111–120. DOI: 10.26442/00403660.2019.07.000045
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье представлены данные о возможностях персонализированного подхода к назначению прямых оральных антикоагулянтов (ПОАК) у пациентов с фибрилляцией предсердий. Подробно обсуждается обзор клинических и научных исследований по возможностям и перспективам фармакогенетического и фармакокинетического тестирования для прогнозирования эффективного и безопасного применения ПОАК.
Ключевые слова: прямые оральные антикоагулянты, апиксабан, дабигатран, ривароксабан, эдоксабан, фармакогенетика, фармакокинетика, персонализированный подход.
Keywords: direct oral anticoagulants, apixaban, dabigatran, rivaroxaban, edoxaban, pharmacogenetics, pharmacokinetics, personalized approach.
Ключевые слова: прямые оральные антикоагулянты, апиксабан, дабигатран, ривароксабан, эдоксабан, фармакогенетика, фармакокинетика, персонализированный подход.
________________________________________________
Keywords: direct oral anticoagulants, apixaban, dabigatran, rivaroxaban, edoxaban, pharmacogenetics, pharmacokinetics, personalized approach.
Список литературы
1. Сычев Д.А., Игнатьев И.В., Емельянов Н.В., Савельева М.И., Дмитриев В.А., Кукес В.Г., Герасимова К.В. Фармакогенетическое тестирование: первые шаги в реальной клинической практике и проблемы стандартизации. Проблемы стандартизации в здравоохранении. 2009;1:43-55 [Sychev DA, Ignatiev IV, Emelyanov NV, et al. Pharmacogenetic testing: first steps in real practice and problems of standardization. Problemy standartizacii v zdravoohranenii. 2009;1:43-55 (In Russ.)].
2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):2893-962. doi:10.1093/europace/euw295
3. Инструкция по применению лекарственного препарата Прадакса. Государственный реестр лекарственных средств. Доступно по: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e4817690-bf14-4e4e-9562-256d415636c7&t=. Ссылка активна на 25.10.2018 [State Register of Medicinal Remedies. Pradaxa (dabigatran): full prescribing information. Available at: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=e4817690-bf14-4e4e-9562-256d415636c7&t=. Accessed by 25.10.2018 (In Russ.)].
4. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104
5. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009 May;157(5):805-10.e1-2. doi: 10.1016/j.ahj.2009.02.005
6. Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013 Apr 2;127(13):1404-12. doi: 10.1161/CIR CULATIONAHA.112.001233
7. Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C, Carraro P, Salomone L, Paniccia R, Paoletti O, Poli D, Palareti G. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. Thromb Res. 2016 Jan;137:178-83. doi: 10.1016/j.thromres.2015.12.001
8. PharmGKB. Available at: https://www.pharmgkb.org/chemical/PA1651 10351/clinicalAnnotation. Accessed October 24, 2018.
9. Merali Z, Ross S, Paré G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metabol Drug Interact. 2014;29(3):143-51. doi: 10.1515/dmdi-2014-0009
10. Dimatteo C, D'Andrea G, Vecchione G, Paoletti O, Cappucci F, Tiscia GL, Buono M, Grandone E, Testa S, Margaglione M. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016 Aug; 144:1-5. doi: 10.1016/j.thromres.2016.05.025
11. Мещеряков Ю.В., Чертовских Я.В., Сычёв Д.А. Фармакогенетика нового орального антикоагулянта дабигатрана - роль полиморфизма rs2244613 CES1 в развитии нежелательных побочных реакций. Фармакогенетика и фармакогеномика. 2017;2:18-9 [Meshheryakov YV, Chertovskikh YV, Sychev DА. Farmakogenetika novogo oral'nogo antikoagulyanta dabigatrana – rol' polimorfizma rs2244613 CES1 v razvitii nezhelatel'nykh pobochnykh reaktsij. Farmakogenetika i farmakogenomika. 2017;2:18-9 (In Russ.)].
12. Сычев Д.А., Казаков Р.Е., Отделенов В.А., Прокофьев А.Б. Прикладные аспекты применения фармакогенетического тестирования для персонализации применения пероральных антикоагулянтов в российских условиях. Рациональная фармакотерапия в кардиологии. 2013;9(5):525-31 [Sychev DA, Kazakov RE, Otdelenov VA, Prokofiev AB. Applications of pharmacogenetic testing for personalization of therapy with oral anticoagulants in Russia. Ration Pharmacother Cardiol. 2013;9(5):525-31 (In Russ.)]. doi: 10.20996/1819-6446-2013-9-5-525-531
13. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2011;26(1):27-32. doi: 10.1111/j.1472-8206. 2011.00981.x
14. Kubitza D, Becka M, Roth A, Mueck W. The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor. J Clin Pharmacol. 2013;53(3):249-55. doi: 10.1002/jcph.5
15. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects. J Clini Pharmacol. 2007;47(2):218-26. doi: 10.1177/009127000626058
16. Инструкция по применению лекарственного препарата Ксарелто. Государственный реестр лекарственных средств. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=732bced6-0374-4deb-a882-c6745d527c8d&a.... Ссылка активна на 24.10.2018 [State Register of Medicinal Remedies. Xarelto (rivaroxaban): full prescribing information. Available at: https://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=732bced6-0374-4deb-a882-c6745d527c8d&t=. Accessed by 24.10.2018 (In Russ.)].
17. Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89-98. doi: 10.1111/bcp.12054
18. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) an oral, direct Factor Xa inhibitor has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63(4):469-76. doi: 10.1111/j.1365-2125.2006.02776.x
19. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin. J Clin Pharmacol. 2006;46(9):981-90. doi: 10.1177/0091270006292127
20. Kubitza D, Becka M, Mück W, Schwers S. Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study. Pharmaceuticals. 2012;5(3):279-96. doi: 10.3390/ph5030279
21. Kubitza D, Becka M, Schwers S, Voith B. Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects. Clin Pharmacol Drug Dev. 2013;2(3):270-7. doi: 10.1002/cpdd.26
22. Kubitza D, Becka M, Mück W, Krätzschmar J. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects. Br J Clin Pharmacol. 2014;78(2):353-63. doi: 10.1111/bcp.12349
23. Kubitza D, Becka M, Roth A, Mueck W. Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor – and Digoxin or Atorvastatin in Healthy Subjects. J International Med Research. 2012;40(5):1688-707. doi: 10.1177/03000 6051204000508
24. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66. doi: 10.1111/ bcp.12075
25. Maier C, Duncan A, Hill C. Pharmacogenetics in Oral Antithrombotic Therapy. Clin Lab Med. 2016;36(3):461-72. doi: 10.1016/j.cll.2016.05. 002
26. Sychev DA, Vardanyan A, Rozhkov A, Hachatryan E, Badanyan A, Smirnov V, Ananichuk A, Denisenko N. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-4. doi: 10.1089/gtmb.2017.0152
27. Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thrombosis and Haemostasis. 2017;15(2):273-83. doi: 10.1111/jth.1357
28. Крюков А.В., Сычев Д.А., Терещенко О.В. Фармакогенетические аспекты применения новых оральных антикоагулянтов. Рациональная фармакотерапия в кардиологии. 2017;13(3):416-21 [Kryukov AV, Sychev DA, Tereshchenko OV. Pharmacogenetic Aspects of New Oral Anticoagulants Application. Rational Pharmacotherapy in Cardiology. 2017;13(3):416-21 (In Russ.)]. doi: 10.20996/1819-6446-2017-13-3-416-421
29. Ing Lorenzini K, Daali Y, Fontana P, Desmeules J, Samer C. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Front Pharmacol. 2016;7. doi: 10.3389/fphar.2016.00494
30. Dideriksen D, Damkier P, Nybo M. Rivaroxaban non-responders: do plasma measurements have a place? Clinical Chemistry and Laboratory Medicine (CCLM). 2017;56(1). doi: 10.1515/cclm-2017-0473
31. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001;11(3):217-21. doi: 10.1097/00008571-2001040 00-00005
32. Инструкция по применению лекарственного препарата Леветирацетам. Государственный реестр лекарственных средств. Доступно по https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routing Guid= 7277294a-54eb-4b9f-9ebd-9bed37cccfee&t= Ссылка активна на 24.10.2018 [State Register of Medicinal Remedies. Levetiracetam: full prescribing information. Available at: https://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routing Guid=7277294a-54eb-4b9f-9ebd-9bed37cccfee&t=. Accessed by 24.10.2018 (In Russ.)].
33. Stöllberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016;126:98-101. doi: 10.1016/j.eplepsyres.2016.06.003
34. Gnoth M, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban. J Pharmacology and Experimental Therapeutics. 2011;338(1):372-80. doi: 10.1124/jpet.111.180240
35. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib. JNCI: J National Cancer Institute. 2006;98(23):1739-42. doi: 10.1093/jnci/ djj469
36. Gong I, Mansell S, Kim R. Absence of both MDR1 (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry. Basic Clin Pharmacol Toxicol. 2012;112(3):164-70. doi: 10.1111/bcpt.12005
37. Sim S, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010;4(4):278. doi: 10.1186/1479-7364-4-4-278
38. O’Connor C, Kiernan T, Yan B. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017;13(7):725-39. doi: 10.1080/17425255.2017.1338274
39. Инструкция по применению лекарственного препарата Эликвис. Государственный реестр лекарственных средств. Доступно по: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b0cb1df0-3494-4405-88fd-78b9995872fd&t= Ссылка активна на 24.10.2018 [State Register of Medicinal Remedies. Eliquis (Apixaban): full prescribing information. Available at: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=b0cb1df0-3494-4405-88fd-78b9995872fd&t= Accessed by 24.10.2018 (In Russ.)].
40. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. ARISTOTLE Committees and Investigators. Committees and Investigators: apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011 Sep;365:981-92. doi: 10.1056/NEJMoa1107039
41. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2011;364:806-17. doi: 10.1056/NEJMoa1007432
42. Frost CE, Song Y, Shenker A, Wang J, Barrett YC, Schuster A, Harris SI, LaCreta F. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet. 2015 Jun;54(6):651-62. doi: 10.1007/s40262-014-0228-0
43. Chang M, Yu Z, Shenker A. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016 May;56(5):637-45. doi: 10.1002/jcph.633
44. Mavrakanas TA, Samer CF, Nessim SJ. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. J Am Soc Nephrol. 2017 Jul;28(7):2241-8. doi: 10.1681/ASN.2016090980
45. Di Minno A, Frigerio B, Spadarella G. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev. 2017 Jul;31(4):193-203. doi: 10.1016/j.blre.2017.02.001
46. Kryukov AV, Sychev DA, Andreev DA, Ryabova AV, Denisenko NP, Loskutnikov MA, Vinogradov OI, Domashenko MA. The pharmacokinetics of apixaban in patients with cardioembolic stroke in acute phase. Ration Pharmacother Cardiol. 2016;12(3):253-9. doi: 10.20996/1819-6446-2016-12-3-253-259
47. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ. In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies. Drug Metab Dispos. 2010;38:448-58. doi: 10.1124/dmd.109. 029694
48. Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018 Mar 22;11:43-9. doi: 10.2147/ PGPM.S157111
49. Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, Balimane PV, Han YH, Gan J, Frost CE, Humphreys WG. Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban. Drug Metab Dispos. 2013 Apr;41:827-35. doi: 10.1124/dmd.112.050260
50. Dimatteo C, D'Andrea G, Vecchione G. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thromb Res. 2016 Sep;145:24-6. doi: 10.1016/j.thromres.2016.07.005
51. Ueshima S, Hirab D, Fujii R. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics. 2017 Sep;27(9):329-36. doi: 10.1097/FPC.0000000000000294
52. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-41. doi: 10.1160/TH10-01-0066
53. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013;369:2093-104. doi: 10.1056/NEJMoa1310907
54. Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015 Dec;55(12):1395-405. doi: 10.1002/jcph.550
55. Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016 Jun;55(6):641-55. doi: 10.1007/s40262-015-0342-7
56. Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. Circ J. 2015;79(7):1486-95. doi: 10.1253/circj.CJ-14-0942
57. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013 Oct;13(5):331-42. doi: 10.1007/s40256-013-0029-0
58. Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, Murphy SA, Lee J, Mercuri MF, Giugliano RP, Antman EM, Braunwald E, Sabatine MS. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 6;385(9984):2280-7. doi: 10.1016/S0140-6736(14)61994-2
59. Vandell AG, Walker J, Brown KS, Zhang G, Lin M, Grosso MA, Mercuri MF. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. Heart. 2017 Nov;103(22):1800-5. doi: 10.1136/heartjnl-2016-310901
60. Vandell AG, Lee J, Shi M, Rubets I, Brown KS, Walker JR. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure. Pharmacogenomics J. 2018 Jan;18(1):153-9. doi: 10.1038/tpj.2016.82
61. Savaysa (edoxaban) tablets [prescribing information]. Parisippany, NJ: Daiichi Sankyo, Inc; 2015. Available at: https://savaysahcp.com/nvaf-safety-and-efficacy. Accessed October 24, 2018.
62. Сайт для расчета дозировки варфарина [Электронный ресурс] Доступно по: http://warfarindosing.org/Source/Home.aspx. Ссылка активна на 10.06.2019 [Site for calculating the dosage of warfarin. Available at: http://warfarindosing.org/Source/Home.aspx. Accessed by 10.06.2019 (In Russ.)].
2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):2893-962. doi:10.1093/europace/euw295
3. [State Register of Medicinal Remedies. Pradaxa (dabigatran): full prescribing information. Available at: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=e4817690-bf14-4e4e-9562-256d415636c7&t=. Accessed by 25.10.2018 (In Russ.)].
4. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104
5. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009 May;157(5):805-10.e1-2. doi: 10.1016/j.ahj.2009.02.005
6. Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013 Apr 2;127(13):1404-12. doi: 10.1161/CIR CULATIONAHA.112.001233
7. Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C, Carraro P, Salomone L, Paniccia R, Paoletti O, Poli D, Palareti G. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. Thromb Res. 2016 Jan;137:178-83. doi: 10.1016/j.thromres.2015.12.001
8. PharmGKB. Available at: https://www.pharmgkb.org/chemical/PA1651 10351/clinicalAnnotation. Accessed October 24, 2018.
9. Merali Z, Ross S, Paré G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metabol Drug Interact. 2014;29(3):143-51. doi: 10.1515/dmdi-2014-0009
10. Dimatteo C, D'Andrea G, Vecchione G, Paoletti O, Cappucci F, Tiscia GL, Buono M, Grandone E, Testa S, Margaglione M. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016 Aug; 144:1-5. doi: 10.1016/j.thromres.2016.05.025
11. [Meshheryakov YV, Chertovskikh YV, Sychev DА. Farmakogenetika novogo oral'nogo antikoagulyanta dabigatrana – rol' polimorfizma rs2244613 CES1 v razvitii nezhelatel'nykh pobochnykh reaktsij. Farmakogenetika i farmakogenomika. 2017;2:18-9 (In Russ.)].
12. [Sychev DA, Kazakov RE, Otdelenov VA, Prokofiev AB. Applications of pharmacogenetic testing for personalization of therapy with oral anticoagulants in Russia. Ration Pharmacother Cardiol. 2013;9(5):525-31 (In Russ.)]. doi: 10.20996/1819-6446-2013-9-5-525-531
13. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2011;26(1):27-32. doi: 10.1111/j.1472-8206. 2011.00981.x
14. Kubitza D, Becka M, Roth A, Mueck W. The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor. J Clin Pharmacol. 2013;53(3):249-55. doi: 10.1002/jcph.5
15. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects. J Clini Pharmacol. 2007;47(2):218-26. doi: 10.1177/009127000626058
16. [State Register of Medicinal Remedies. Xarelto (rivaroxaban): full prescribing information. Available at: https://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=732bced6-0374-4deb-a882-c6745d527c8d&t=. Accessed by 24.10.2018 (In Russ.)].
17. Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89-98. doi: 10.1111/bcp.12054
18. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) an oral, direct Factor Xa inhibitor has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63(4):469-76. doi: 10.1111/j.1365-2125.2006.02776.x
19. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin. J Clin Pharmacol. 2006;46(9):981-90. doi: 10.1177/0091270006292127
20. Kubitza D, Becka M, Mück W, Schwers S. Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study. Pharmaceuticals. 2012;5(3):279-96. doi: 10.3390/ph5030279
21. Kubitza D, Becka M, Schwers S, Voith B. Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects. Clin Pharmacol Drug Dev. 2013;2(3):270-7. doi: 10.1002/cpdd.26
22. Kubitza D, Becka M, Mück W, Krätzschmar J. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects. Br J Clin Pharmacol. 2014;78(2):353-63. doi: 10.1111/bcp.12349
23. Kubitza D, Becka M, Roth A, Mueck W. Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor – and Digoxin or Atorvastatin in Healthy Subjects. J International Med Research. 2012;40(5):1688-707. doi: 10.1177/03000 6051204000508
24. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66. doi: 10.1111/ bcp.12075
25. Maier C, Duncan A, Hill C. Pharmacogenetics in Oral Antithrombotic Therapy. Clin Lab Med. 2016;36(3):461-72. doi: 10.1016/j.cll.2016.05. 002
26. Sychev DA, Vardanyan A, Rozhkov A, Hachatryan E, Badanyan A, Smirnov V, Ananichuk A, Denisenko N. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-4. doi: 10.1089/gtmb.2017.0152
27. Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thrombosis and Haemostasis. 2017;15(2):273-83. doi: 10.1111/jth.1357
28. [Kryukov AV, Sychev DA, Tereshchenko OV. Pharmacogenetic Aspects of New Oral Anticoagulants Application. Rational Pharmacotherapy in Cardiology. 2017;13(3):416-21 (In Russ.)]. doi: 10.20996/1819-6446-2017-13-3-416-421
29. Ing Lorenzini K, Daali Y, Fontana P, Desmeules J, Samer C. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Front Pharmacol. 2016;7. doi: 10.3389/fphar.2016.00494
30. Dideriksen D, Damkier P, Nybo M. Rivaroxaban non-responders: do plasma measurements have a place? Clinical Chemistry and Laboratory Medicine (CCLM). 2017;56(1). doi: 10.1515/cclm-2017-0473
31. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001;11(3):217-21. doi: 10.1097/00008571-2001040 00-00005
32. [State Register of Medicinal Remedies. Levetiracetam: full prescribing information. Available at: https://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routing Guid=7277294a-54eb-4b9f-9ebd-9bed37cccfee&t=. Accessed by 24.10.2018 (In Russ.)].
33. Stöllberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016;126:98-101. doi: 10.1016/j.eplepsyres.2016.06.003
34. Gnoth M, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban. J Pharmacology and Experimental Therapeutics. 2011;338(1):372-80. doi: 10.1124/jpet.111.180240
35. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib. JNCI: J National Cancer Institute. 2006;98(23):1739-42. doi: 10.1093/jnci/ djj469
36. Gong I, Mansell S, Kim R. Absence of both MDR1 (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry. Basic Clin Pharmacol Toxicol. 2012;112(3):164-70. doi: 10.1111/bcpt.12005
37. Sim S, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010;4(4):278. doi: 10.1186/1479-7364-4-4-278
38. O’Connor C, Kiernan T, Yan B. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017;13(7):725-39. doi: 10.1080/17425255.2017.1338274
39. [State Register of Medicinal Remedies. Eliquis (Apixaban): full prescribing information. Available at: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=b0cb1df0-3494-4405-88fd-78b9995872fd&t= Accessed by 24.10.2018 (In Russ.)].
40. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. ARISTOTLE Committees and Investigators. Committees and Investigators: apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011 Sep;365:981-92. doi: 10.1056/NEJMoa1107039
41. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2011;364:806-17. doi: 10.1056/NEJMoa1007432
42. Frost CE, Song Y, Shenker A, Wang J, Barrett YC, Schuster A, Harris SI, LaCreta F. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet. 2015 Jun;54(6):651-62. doi: 10.1007/s40262-014-0228-0
43. Chang M, Yu Z, Shenker A. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016 May;56(5):637-45. doi: 10.1002/jcph.633
44. Mavrakanas TA, Samer CF, Nessim SJ. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. J Am Soc Nephrol. 2017 Jul;28(7):2241-8. doi: 10.1681/ASN.2016090980
45. Di Minno A, Frigerio B, Spadarella G. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev. 2017 Jul;31(4):193-203. doi: 10.1016/j.blre.2017.02.001
46. Kryukov AV, Sychev DA, Andreev DA, Ryabova AV, Denisenko NP, Loskutnikov MA, Vinogradov OI, Domashenko MA. The pharmacokinetics of apixaban in patients with cardioembolic stroke in acute phase. Ration Pharmacother Cardiol. 2016;12(3):253-9. doi: 10.20996/1819-6446-2016-12-3-253-259
47. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ. In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies. Drug Metab Dispos. 2010;38:448-58. doi: 10.1124/dmd.109. 029694
48. Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018 Mar 22;11:43-9. doi: 10.2147/ PGPM.S157111
49. Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, Balimane PV, Han YH, Gan J, Frost CE, Humphreys WG. Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban. Drug Metab Dispos. 2013 Apr;41:827-35. doi: 10.1124/dmd.112.050260
50. Dimatteo C, D'Andrea G, Vecchione G. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thromb Res. 2016 Sep;145:24-6. doi: 10.1016/j.thromres.2016.07.005
51. Ueshima S, Hirab D, Fujii R. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics. 2017 Sep;27(9):329-36. doi: 10.1097/FPC.0000000000000294
52. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-41. doi: 10.1160/TH10-01-0066
53. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013;369:2093-104. doi: 10.1056/NEJMoa1310907
54. Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015 Dec;55(12):1395-405. doi: 10.1002/jcph.550
55. Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016 Jun;55(6):641-55. doi: 10.1007/s40262-015-0342-7
56. Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. Circ J. 2015;79(7):1486-95. doi: 10.1253/circj.CJ-14-0942
57. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013 Oct;13(5):331-42. doi: 10.1007/s40256-013-0029-0
58. Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, Murphy SA, Lee J, Mercuri MF, Giugliano RP, Antman EM, Braunwald E, Sabatine MS. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 6;385(9984):2280-7. doi: 10.1016/S0140-6736(14)61994-2
59. Vandell AG, Walker J, Brown KS, Zhang G, Lin M, Grosso MA, Mercuri MF. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. Heart. 2017 Nov;103(22):1800-5. doi: 10.1136/heartjnl-2016-310901
60. Vandell AG, Lee J, Shi M, Rubets I, Brown KS, Walker JR. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure. Pharmacogenomics J. 2018 Jan;18(1):153-9. doi: 10.1038/tpj.2016.82
61. Savaysa (edoxaban) tablets [prescribing information]. Parisippany, NJ: Daiichi Sankyo, Inc; 2015. Available at: https://savaysahcp.com/nvaf-safety-and-efficacy. Accessed October 24, 2018.
62. [Site for calculating the dosage of warfarin. Available at: http://warfarindosing.org/Source/Home.aspx. Accessed by 10.06.2019 (In Russ.)].
2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):2893-962. doi:10.1093/europace/euw295
3. Инструкция по применению лекарственного препарата Прадакса. Государственный реестр лекарственных средств. Доступно по: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e4817690-bf14-4e4e-9562-256d415636c7&t=. Ссылка активна на 25.10.2018 [State Register of Medicinal Remedies. Pradaxa (dabigatran): full prescribing information. Available at: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=e4817690-bf14-4e4e-9562-256d415636c7&t=. Accessed by 25.10.2018 (In Russ.)].
4. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104
5. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009 May;157(5):805-10.e1-2. doi: 10.1016/j.ahj.2009.02.005
6. Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013 Apr 2;127(13):1404-12. doi: 10.1161/CIR CULATIONAHA.112.001233
7. Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C, Carraro P, Salomone L, Paniccia R, Paoletti O, Poli D, Palareti G. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. Thromb Res. 2016 Jan;137:178-83. doi: 10.1016/j.thromres.2015.12.001
8. PharmGKB. Available at: https://www.pharmgkb.org/chemical/PA1651 10351/clinicalAnnotation. Accessed October 24, 2018.
9. Merali Z, Ross S, Paré G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metabol Drug Interact. 2014;29(3):143-51. doi: 10.1515/dmdi-2014-0009
10. Dimatteo C, D'Andrea G, Vecchione G, Paoletti O, Cappucci F, Tiscia GL, Buono M, Grandone E, Testa S, Margaglione M. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016 Aug; 144:1-5. doi: 10.1016/j.thromres.2016.05.025
11. Мещеряков Ю.В., Чертовских Я.В., Сычёв Д.А. Фармакогенетика нового орального антикоагулянта дабигатрана - роль полиморфизма rs2244613 CES1 в развитии нежелательных побочных реакций. Фармакогенетика и фармакогеномика. 2017;2:18-9 [Meshheryakov YV, Chertovskikh YV, Sychev DА. Farmakogenetika novogo oral'nogo antikoagulyanta dabigatrana – rol' polimorfizma rs2244613 CES1 v razvitii nezhelatel'nykh pobochnykh reaktsij. Farmakogenetika i farmakogenomika. 2017;2:18-9 (In Russ.)].
12. Сычев Д.А., Казаков Р.Е., Отделенов В.А., Прокофьев А.Б. Прикладные аспекты применения фармакогенетического тестирования для персонализации применения пероральных антикоагулянтов в российских условиях. Рациональная фармакотерапия в кардиологии. 2013;9(5):525-31 [Sychev DA, Kazakov RE, Otdelenov VA, Prokofiev AB. Applications of pharmacogenetic testing for personalization of therapy with oral anticoagulants in Russia. Ration Pharmacother Cardiol. 2013;9(5):525-31 (In Russ.)]. doi: 10.20996/1819-6446-2013-9-5-525-531
13. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2011;26(1):27-32. doi: 10.1111/j.1472-8206. 2011.00981.x
14. Kubitza D, Becka M, Roth A, Mueck W. The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor. J Clin Pharmacol. 2013;53(3):249-55. doi: 10.1002/jcph.5
15. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects. J Clini Pharmacol. 2007;47(2):218-26. doi: 10.1177/009127000626058
16. Инструкция по применению лекарственного препарата Ксарелто. Государственный реестр лекарственных средств. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=732bced6-0374-4deb-a882-c6745d527c8d&a.... Ссылка активна на 24.10.2018 [State Register of Medicinal Remedies. Xarelto (rivaroxaban): full prescribing information. Available at: https://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=732bced6-0374-4deb-a882-c6745d527c8d&t=. Accessed by 24.10.2018 (In Russ.)].
17. Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89-98. doi: 10.1111/bcp.12054
18. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) an oral, direct Factor Xa inhibitor has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63(4):469-76. doi: 10.1111/j.1365-2125.2006.02776.x
19. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin. J Clin Pharmacol. 2006;46(9):981-90. doi: 10.1177/0091270006292127
20. Kubitza D, Becka M, Mück W, Schwers S. Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study. Pharmaceuticals. 2012;5(3):279-96. doi: 10.3390/ph5030279
21. Kubitza D, Becka M, Schwers S, Voith B. Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects. Clin Pharmacol Drug Dev. 2013;2(3):270-7. doi: 10.1002/cpdd.26
22. Kubitza D, Becka M, Mück W, Krätzschmar J. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects. Br J Clin Pharmacol. 2014;78(2):353-63. doi: 10.1111/bcp.12349
23. Kubitza D, Becka M, Roth A, Mueck W. Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor – and Digoxin or Atorvastatin in Healthy Subjects. J International Med Research. 2012;40(5):1688-707. doi: 10.1177/03000 6051204000508
24. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66. doi: 10.1111/ bcp.12075
25. Maier C, Duncan A, Hill C. Pharmacogenetics in Oral Antithrombotic Therapy. Clin Lab Med. 2016;36(3):461-72. doi: 10.1016/j.cll.2016.05. 002
26. Sychev DA, Vardanyan A, Rozhkov A, Hachatryan E, Badanyan A, Smirnov V, Ananichuk A, Denisenko N. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-4. doi: 10.1089/gtmb.2017.0152
27. Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thrombosis and Haemostasis. 2017;15(2):273-83. doi: 10.1111/jth.1357
28. Крюков А.В., Сычев Д.А., Терещенко О.В. Фармакогенетические аспекты применения новых оральных антикоагулянтов. Рациональная фармакотерапия в кардиологии. 2017;13(3):416-21 [Kryukov AV, Sychev DA, Tereshchenko OV. Pharmacogenetic Aspects of New Oral Anticoagulants Application. Rational Pharmacotherapy in Cardiology. 2017;13(3):416-21 (In Russ.)]. doi: 10.20996/1819-6446-2017-13-3-416-421
29. Ing Lorenzini K, Daali Y, Fontana P, Desmeules J, Samer C. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Front Pharmacol. 2016;7. doi: 10.3389/fphar.2016.00494
30. Dideriksen D, Damkier P, Nybo M. Rivaroxaban non-responders: do plasma measurements have a place? Clinical Chemistry and Laboratory Medicine (CCLM). 2017;56(1). doi: 10.1515/cclm-2017-0473
31. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001;11(3):217-21. doi: 10.1097/00008571-2001040 00-00005
32. Инструкция по применению лекарственного препарата Леветирацетам. Государственный реестр лекарственных средств. Доступно по https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routing Guid= 7277294a-54eb-4b9f-9ebd-9bed37cccfee&t= Ссылка активна на 24.10.2018 [State Register of Medicinal Remedies. Levetiracetam: full prescribing information. Available at: https://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routing Guid=7277294a-54eb-4b9f-9ebd-9bed37cccfee&t=. Accessed by 24.10.2018 (In Russ.)].
33. Stöllberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016;126:98-101. doi: 10.1016/j.eplepsyres.2016.06.003
34. Gnoth M, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban. J Pharmacology and Experimental Therapeutics. 2011;338(1):372-80. doi: 10.1124/jpet.111.180240
35. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib. JNCI: J National Cancer Institute. 2006;98(23):1739-42. doi: 10.1093/jnci/ djj469
36. Gong I, Mansell S, Kim R. Absence of both MDR1 (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry. Basic Clin Pharmacol Toxicol. 2012;112(3):164-70. doi: 10.1111/bcpt.12005
37. Sim S, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010;4(4):278. doi: 10.1186/1479-7364-4-4-278
38. O’Connor C, Kiernan T, Yan B. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017;13(7):725-39. doi: 10.1080/17425255.2017.1338274
39. Инструкция по применению лекарственного препарата Эликвис. Государственный реестр лекарственных средств. Доступно по: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b0cb1df0-3494-4405-88fd-78b9995872fd&t= Ссылка активна на 24.10.2018 [State Register of Medicinal Remedies. Eliquis (Apixaban): full prescribing information. Available at: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=b0cb1df0-3494-4405-88fd-78b9995872fd&t= Accessed by 24.10.2018 (In Russ.)].
40. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. ARISTOTLE Committees and Investigators. Committees and Investigators: apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011 Sep;365:981-92. doi: 10.1056/NEJMoa1107039
41. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2011;364:806-17. doi: 10.1056/NEJMoa1007432
42. Frost CE, Song Y, Shenker A, Wang J, Barrett YC, Schuster A, Harris SI, LaCreta F. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet. 2015 Jun;54(6):651-62. doi: 10.1007/s40262-014-0228-0
43. Chang M, Yu Z, Shenker A. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016 May;56(5):637-45. doi: 10.1002/jcph.633
44. Mavrakanas TA, Samer CF, Nessim SJ. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. J Am Soc Nephrol. 2017 Jul;28(7):2241-8. doi: 10.1681/ASN.2016090980
45. Di Minno A, Frigerio B, Spadarella G. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev. 2017 Jul;31(4):193-203. doi: 10.1016/j.blre.2017.02.001
46. Kryukov AV, Sychev DA, Andreev DA, Ryabova AV, Denisenko NP, Loskutnikov MA, Vinogradov OI, Domashenko MA. The pharmacokinetics of apixaban in patients with cardioembolic stroke in acute phase. Ration Pharmacother Cardiol. 2016;12(3):253-9. doi: 10.20996/1819-6446-2016-12-3-253-259
47. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ. In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies. Drug Metab Dispos. 2010;38:448-58. doi: 10.1124/dmd.109. 029694
48. Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018 Mar 22;11:43-9. doi: 10.2147/ PGPM.S157111
49. Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, Balimane PV, Han YH, Gan J, Frost CE, Humphreys WG. Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban. Drug Metab Dispos. 2013 Apr;41:827-35. doi: 10.1124/dmd.112.050260
50. Dimatteo C, D'Andrea G, Vecchione G. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thromb Res. 2016 Sep;145:24-6. doi: 10.1016/j.thromres.2016.07.005
51. Ueshima S, Hirab D, Fujii R. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics. 2017 Sep;27(9):329-36. doi: 10.1097/FPC.0000000000000294
52. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-41. doi: 10.1160/TH10-01-0066
53. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013;369:2093-104. doi: 10.1056/NEJMoa1310907
54. Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015 Dec;55(12):1395-405. doi: 10.1002/jcph.550
55. Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016 Jun;55(6):641-55. doi: 10.1007/s40262-015-0342-7
56. Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. Circ J. 2015;79(7):1486-95. doi: 10.1253/circj.CJ-14-0942
57. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013 Oct;13(5):331-42. doi: 10.1007/s40256-013-0029-0
58. Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, Murphy SA, Lee J, Mercuri MF, Giugliano RP, Antman EM, Braunwald E, Sabatine MS. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 6;385(9984):2280-7. doi: 10.1016/S0140-6736(14)61994-2
59. Vandell AG, Walker J, Brown KS, Zhang G, Lin M, Grosso MA, Mercuri MF. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. Heart. 2017 Nov;103(22):1800-5. doi: 10.1136/heartjnl-2016-310901
60. Vandell AG, Lee J, Shi M, Rubets I, Brown KS, Walker JR. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure. Pharmacogenomics J. 2018 Jan;18(1):153-9. doi: 10.1038/tpj.2016.82
61. Savaysa (edoxaban) tablets [prescribing information]. Parisippany, NJ: Daiichi Sankyo, Inc; 2015. Available at: https://savaysahcp.com/nvaf-safety-and-efficacy. Accessed October 24, 2018.
62. Сайт для расчета дозировки варфарина [Электронный ресурс] Доступно по: http://warfarindosing.org/Source/Home.aspx. Ссылка активна на 10.06.2019 [Site for calculating the dosage of warfarin. Available at: http://warfarindosing.org/Source/Home.aspx. Accessed by 10.06.2019 (In Russ.)].
________________________________________________
2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):2893-962. doi:10.1093/europace/euw295
3. [State Register of Medicinal Remedies. Pradaxa (dabigatran): full prescribing information. Available at: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=e4817690-bf14-4e4e-9562-256d415636c7&t=. Accessed by 25.10.2018 (In Russ.)].
4. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104
5. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009 May;157(5):805-10.e1-2. doi: 10.1016/j.ahj.2009.02.005
6. Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013 Apr 2;127(13):1404-12. doi: 10.1161/CIR CULATIONAHA.112.001233
7. Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C, Carraro P, Salomone L, Paniccia R, Paoletti O, Poli D, Palareti G. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. Thromb Res. 2016 Jan;137:178-83. doi: 10.1016/j.thromres.2015.12.001
8. PharmGKB. Available at: https://www.pharmgkb.org/chemical/PA1651 10351/clinicalAnnotation. Accessed October 24, 2018.
9. Merali Z, Ross S, Paré G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metabol Drug Interact. 2014;29(3):143-51. doi: 10.1515/dmdi-2014-0009
10. Dimatteo C, D'Andrea G, Vecchione G, Paoletti O, Cappucci F, Tiscia GL, Buono M, Grandone E, Testa S, Margaglione M. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016 Aug; 144:1-5. doi: 10.1016/j.thromres.2016.05.025
11. [Meshheryakov YV, Chertovskikh YV, Sychev DА. Farmakogenetika novogo oral'nogo antikoagulyanta dabigatrana – rol' polimorfizma rs2244613 CES1 v razvitii nezhelatel'nykh pobochnykh reaktsij. Farmakogenetika i farmakogenomika. 2017;2:18-9 (In Russ.)].
12. [Sychev DA, Kazakov RE, Otdelenov VA, Prokofiev AB. Applications of pharmacogenetic testing for personalization of therapy with oral anticoagulants in Russia. Ration Pharmacother Cardiol. 2013;9(5):525-31 (In Russ.)]. doi: 10.20996/1819-6446-2013-9-5-525-531
13. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2011;26(1):27-32. doi: 10.1111/j.1472-8206. 2011.00981.x
14. Kubitza D, Becka M, Roth A, Mueck W. The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor. J Clin Pharmacol. 2013;53(3):249-55. doi: 10.1002/jcph.5
15. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects. J Clini Pharmacol. 2007;47(2):218-26. doi: 10.1177/009127000626058
16. [State Register of Medicinal Remedies. Xarelto (rivaroxaban): full prescribing information. Available at: https://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=732bced6-0374-4deb-a882-c6745d527c8d&t=. Accessed by 24.10.2018 (In Russ.)].
17. Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89-98. doi: 10.1111/bcp.12054
18. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) an oral, direct Factor Xa inhibitor has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63(4):469-76. doi: 10.1111/j.1365-2125.2006.02776.x
19. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin. J Clin Pharmacol. 2006;46(9):981-90. doi: 10.1177/0091270006292127
20. Kubitza D, Becka M, Mück W, Schwers S. Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study. Pharmaceuticals. 2012;5(3):279-96. doi: 10.3390/ph5030279
21. Kubitza D, Becka M, Schwers S, Voith B. Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects. Clin Pharmacol Drug Dev. 2013;2(3):270-7. doi: 10.1002/cpdd.26
22. Kubitza D, Becka M, Mück W, Krätzschmar J. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects. Br J Clin Pharmacol. 2014;78(2):353-63. doi: 10.1111/bcp.12349
23. Kubitza D, Becka M, Roth A, Mueck W. Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor – and Digoxin or Atorvastatin in Healthy Subjects. J International Med Research. 2012;40(5):1688-707. doi: 10.1177/03000 6051204000508
24. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66. doi: 10.1111/ bcp.12075
25. Maier C, Duncan A, Hill C. Pharmacogenetics in Oral Antithrombotic Therapy. Clin Lab Med. 2016;36(3):461-72. doi: 10.1016/j.cll.2016.05. 002
26. Sychev DA, Vardanyan A, Rozhkov A, Hachatryan E, Badanyan A, Smirnov V, Ananichuk A, Denisenko N. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-4. doi: 10.1089/gtmb.2017.0152
27. Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thrombosis and Haemostasis. 2017;15(2):273-83. doi: 10.1111/jth.1357
28. [Kryukov AV, Sychev DA, Tereshchenko OV. Pharmacogenetic Aspects of New Oral Anticoagulants Application. Rational Pharmacotherapy in Cardiology. 2017;13(3):416-21 (In Russ.)]. doi: 10.20996/1819-6446-2017-13-3-416-421
29. Ing Lorenzini K, Daali Y, Fontana P, Desmeules J, Samer C. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Front Pharmacol. 2016;7. doi: 10.3389/fphar.2016.00494
30. Dideriksen D, Damkier P, Nybo M. Rivaroxaban non-responders: do plasma measurements have a place? Clinical Chemistry and Laboratory Medicine (CCLM). 2017;56(1). doi: 10.1515/cclm-2017-0473
31. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001;11(3):217-21. doi: 10.1097/00008571-2001040 00-00005
32. [State Register of Medicinal Remedies. Levetiracetam: full prescribing information. Available at: https://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routing Guid=7277294a-54eb-4b9f-9ebd-9bed37cccfee&t=. Accessed by 24.10.2018 (In Russ.)].
33. Stöllberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016;126:98-101. doi: 10.1016/j.eplepsyres.2016.06.003
34. Gnoth M, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban. J Pharmacology and Experimental Therapeutics. 2011;338(1):372-80. doi: 10.1124/jpet.111.180240
35. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib. JNCI: J National Cancer Institute. 2006;98(23):1739-42. doi: 10.1093/jnci/ djj469
36. Gong I, Mansell S, Kim R. Absence of both MDR1 (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry. Basic Clin Pharmacol Toxicol. 2012;112(3):164-70. doi: 10.1111/bcpt.12005
37. Sim S, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010;4(4):278. doi: 10.1186/1479-7364-4-4-278
38. O’Connor C, Kiernan T, Yan B. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017;13(7):725-39. doi: 10.1080/17425255.2017.1338274
39. [State Register of Medicinal Remedies. Eliquis (Apixaban): full prescribing information. Available at: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=b0cb1df0-3494-4405-88fd-78b9995872fd&t= Accessed by 24.10.2018 (In Russ.)].
40. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. ARISTOTLE Committees and Investigators. Committees and Investigators: apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011 Sep;365:981-92. doi: 10.1056/NEJMoa1107039
41. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2011;364:806-17. doi: 10.1056/NEJMoa1007432
42. Frost CE, Song Y, Shenker A, Wang J, Barrett YC, Schuster A, Harris SI, LaCreta F. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet. 2015 Jun;54(6):651-62. doi: 10.1007/s40262-014-0228-0
43. Chang M, Yu Z, Shenker A. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016 May;56(5):637-45. doi: 10.1002/jcph.633
44. Mavrakanas TA, Samer CF, Nessim SJ. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. J Am Soc Nephrol. 2017 Jul;28(7):2241-8. doi: 10.1681/ASN.2016090980
45. Di Minno A, Frigerio B, Spadarella G. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev. 2017 Jul;31(4):193-203. doi: 10.1016/j.blre.2017.02.001
46. Kryukov AV, Sychev DA, Andreev DA, Ryabova AV, Denisenko NP, Loskutnikov MA, Vinogradov OI, Domashenko MA. The pharmacokinetics of apixaban in patients with cardioembolic stroke in acute phase. Ration Pharmacother Cardiol. 2016;12(3):253-9. doi: 10.20996/1819-6446-2016-12-3-253-259
47. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ. In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies. Drug Metab Dispos. 2010;38:448-58. doi: 10.1124/dmd.109. 029694
48. Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018 Mar 22;11:43-9. doi: 10.2147/ PGPM.S157111
49. Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, Balimane PV, Han YH, Gan J, Frost CE, Humphreys WG. Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban. Drug Metab Dispos. 2013 Apr;41:827-35. doi: 10.1124/dmd.112.050260
50. Dimatteo C, D'Andrea G, Vecchione G. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thromb Res. 2016 Sep;145:24-6. doi: 10.1016/j.thromres.2016.07.005
51. Ueshima S, Hirab D, Fujii R. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics. 2017 Sep;27(9):329-36. doi: 10.1097/FPC.0000000000000294
52. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-41. doi: 10.1160/TH10-01-0066
53. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013;369:2093-104. doi: 10.1056/NEJMoa1310907
54. Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015 Dec;55(12):1395-405. doi: 10.1002/jcph.550
55. Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016 Jun;55(6):641-55. doi: 10.1007/s40262-015-0342-7
56. Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. Circ J. 2015;79(7):1486-95. doi: 10.1253/circj.CJ-14-0942
57. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013 Oct;13(5):331-42. doi: 10.1007/s40256-013-0029-0
58. Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, Murphy SA, Lee J, Mercuri MF, Giugliano RP, Antman EM, Braunwald E, Sabatine MS. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 6;385(9984):2280-7. doi: 10.1016/S0140-6736(14)61994-2
59. Vandell AG, Walker J, Brown KS, Zhang G, Lin M, Grosso MA, Mercuri MF. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. Heart. 2017 Nov;103(22):1800-5. doi: 10.1136/heartjnl-2016-310901
60. Vandell AG, Lee J, Shi M, Rubets I, Brown KS, Walker JR. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure. Pharmacogenomics J. 2018 Jan;18(1):153-9. doi: 10.1038/tpj.2016.82
61. Savaysa (edoxaban) tablets [prescribing information]. Parisippany, NJ: Daiichi Sankyo, Inc; 2015. Available at: https://savaysahcp.com/nvaf-safety-and-efficacy. Accessed October 24, 2018.
62. [Site for calculating the dosage of warfarin. Available at: http://warfarindosing.org/Source/Home.aspx. Accessed by 10.06.2019 (In Russ.)].
Авторы
А.И. Скрипка, В.В. Когай, А.И. Листратов, А.А. Соколова, Д.А. Напалков, В.В. Фомин
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
________________________________________________
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.